Ceftibuten

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Ceftibuten
File:Ceftibuten.svg
Clinical data
Trade namesCedax
AHFS/Drugs.comMonograph
MedlinePlusa698023
ATC code
Identifiers
  • (6R,7R)-7-([(Z)-2-(2-Amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC15H14N4O6S2
Molar mass410.42 g·mol−1
3D model (JSmol)
  • O=C2N1/C(=C\CS[C@@H]1[C@@H]2NC(=O)C(=C/CC(=O)O)\c3nc(sc3)N)C(=O)O
  • InChI=1S/C15H14N4O6S2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25)/b6-1-/t10-,13-/m1/s1 checkY
  • Key:UNJFKXSSGBWRBZ-BJCIPQKHSA-N checkY
  (verify)

Ceftibuten is a third-generation cephalosporin antibiotic.[1][2] It is an orally administered agent, with two dosage forms, capsule or oral suspension. It is marketed by Pernix Therapeutics under the trade name Cedax.

Medical uses

[edit | edit source]
Main article: Cephalosporin

Ceftibuten is used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis. It is also indicated for pneumonia, infections of the urinary tract, enteritis, and gastroenteritis.[citation needed]

Adverse effects

[edit | edit source]

In 3,000 patients, ceftibuten was well tolerated. The most frequent reactions were gastrointestinal and nausea.[citation needed]

Susceptibility

[edit | edit source]

Ceftibuten is active against Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Klebsiella pneumoniae, K. oxytoca, Proteus vulgaris, P. mirabilis, P. providence, Salmonella sp., Shigella sp., Enterobacter sp., and Streptococcus sp.[citation needed]

The following represents minimum inhibitory concentration (MIC) susceptibility data for a few clinically significant microorganisms:

  • Haemophilus influenzae: 0.015–1.0 μg/ml
  • Moraxella catarrhalis: 0.5–4.0  μg/ml
  • Streptococcus pneumoniae: 0.5–256 μg/ml [3]

References

[edit | edit source]
  1. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  2. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  3. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
[edit | edit source]
Retrieved from "http://70.231.62.181/index.php?title=Ceftibuten&oldid=13303832"